Gefitinib in Combination with Gemcitabine and Carboplatin in Never Smokers with Non-small Cell Lung Carcinoma: A Retrospective Analysis

The addition of gefitinib to first-line chemotherapy improved progression-free survival and overall survival when used as a first-line therapy in never smokers with advanced NSCLC in this retrospective study. A prospective randomized phase III study is needed to confirm this finding.